Are subtype differences important in HIV drug resistance?

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 636-643

  Lessells, R J ^a,b   Katzenstein, D K ^c   De Oliveira, T ^a,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; ETRAVIRINE; INDINAVIR; LOPINAVIR; MARAVIROC; MK 2048; NELFINAVIR; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHYLOGENY; PRIORITY JOURNAL;

EID: 84867397003     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.08.006     Document Type: Review

References (54)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) World AIDS Day Report 2011 2011 UNAIDS Geneva, Switzerland
2. R.L. Hamers, C. Kityo, J.M. Lange, T.F. Wit, and P. Mugyenyi Global threat from drug resistant HIV in sub-Saharan Africa BMJ 344 2012 e4159
3. J. Hemelaar, E. Gouws, P.D. Ghys, and S. Osmanov Global trends in molecular epidemiology of HIV-1 during 2000-2007 AIDS 25 2011 679 689
4. P.M. Sharp, and B.H. Hahn The evolution of HIV-1 and the origin of AIDS Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 365 2010 2487 2494
5. D.M. Tebit, and E.J. Arts Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease Lancet Infectious Diseases 11 2011 45 56
6. M. Peeters, A.F. Aghokeng, and E. Delaporte Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 16 2010 1525 1531
7. J. Hemelaar The origin and diversity of the HIV-1 pandemic Trends in Molecular Medicine 18 2012 182 192
8. B.G. Brenner, M. Lowe, D. Moisi, I. Hardy, S. Gagnon, H. Charest, J.G. Baril, M.A. Wainberg, and M. Roger Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors Journal of Medical Virology 83 2011 751 759
9. D.N. Chilton, H. Castro, S. Lattimore, L.J. Harrison, E. Fearnhill, V. Delpech, B. Rice, D. Pillay, and D.T. Dunn HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom Antiviral Therapy 15 2010 985 991
10. J. Fox, H. Castro, S. Kaye, M. McClure, J.N. Weber, and S. Fidler Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK AIDS 24 2010 2397 2401
11. M.A. Wainberg, G.J. Zaharatos, and B.G. Brenner Development of antiretroviral drug resistance New England Journal of Medicine 365 2011 637 646
12. S.L. Kosakovsky Pond, D. Posada, E. Stawiski, C. Chappey, A.F. Poon, G. Hughes, E. Fearnhill, M.B. Gravenor, A.J. Leigh Brown, and S.D. Frost An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1 PLoS Computational Biology 5 2009 e1000581
13. T. de Oliveira, R.W. Shafer, and C. Seebregts Public database for HIV drug resistance in southern Africa Nature 464 2010 673
14. G.L. Melikian, S.Y. Rhee, J. Taylor, W.J. Fessel, D. Kaufman, W. Towner, P.V. Troia-Cancio, A. Zolopa, G.K. Robbins, and R. Kagan Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility Antimicrobial Agents and Chemotherapy 56 2012 2305 2313
15. S.Y. Rhee, J. Taylor, W.J. Fessel, D. Kaufman, W. Towner, P. Troia, P. Ruane, J. Hellinger, V. Shirvani, and A. Zolopa HIV-1 protease mutations and protease inhibitor cross-resistance Antimicrobial Agents and Chemotherapy 54 2010 4253 4261
16. D. Coutsinos, C.F. Invernizzi, H. Xu, B.G. Brenner, and M.A. Wainberg Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1 Antiviral Chemistry and Chemotherapy 20 2010 117 131
17. D. Coutsinos, C.F. Invernizzi, D. Moisi, M. Oliveira, J.L. Martinez-Cajas, B.G. Brenner, and M.A. Wainberg A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1 PLoS ONE 6 2011 e20208
18. M.J. Kozal, J. Chiarella, E.P. St John, E.A. Moreno, B.B. Simen, T.E. Arnold, and M. Lataillade Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels Antiviral Therapy 16 2011 925 929
19. J.F. Li, J.T. Lipscomb, X. Wei, N.A. Martinson, L. Morris, W. Heneine, and J.A. Johnson Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections Journal of Infectious Diseases 203 2011 798 802
20. T.A. Toni, B.G. Brenner, E.L. Asahchop, M. Ntemgwa, D. Moisi, and M.A. Wainberg Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1 Antimicrobial Agents and Chemotherapy 54 2010 907 911
21. P. Recordon-Pinson, J. Papuchon, S. Reigadas, A. Deshpande, and H. Fleury K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data PLoS ONE 7 2012 e36549
22. V. Varghese, E. Wang, F. Babrzadeh, M.H. Bachmann, R. Shahriar, T. Liu, S.J. Mappala, B. Gharizadeh, W.J. Fessel, and D. Katzenstein Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation PLoS ONE 5 2010 e10992
23. H. Sunpath, B. Wu, M. Gordon, J. Hampton, B. Johnson, M.Y. Moosa, C. Ordonez, D.R. Kuritzkes, and V.C. Marconi High rate of K65R for ART naive patients with subtype C HIV infection failing a TDF-containing first-line regimen in South Africa AIDS 26 2012 1679 1684
24. M.W. Tang, P.J. Kanki, and R.W. Shafer A review of the virological efficacy of the 4 world health organization-recommended tenofovir-containing regimens for initial HIV therapy Clinical Infectious Diseases 54 2012 862 875
25. V. Bansal, K.J. Metzner, B. Niederost, C. Leemann, J. Boni, H.F. Gunthard, and J.S. Fehr Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant Emerging Infectious Diseases 17 2011 1966 1968
26. S.H. Eshleman, D.R. Hoover, S. Chen, S.E. Hudelson, L.A. Guay, A. Mwatha, S.A. Fiscus, F. Mmiro, P. Musoke, and J.B. Jackson Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP Journal of Infectious Diseases 192 2005 30 36
27. R. Kantor Impact of HIV-1 pol diversity on drug resistance and its clinical implications Current Opinion in Infectious Diseases 19 2006 594 606
28. J. Vingerhoets, H. Azijn, L. Tambuyzer, I. Dierynck, S. De Meyer, L. Rimsky, S. Nijs, G. De Smedt, M.P. de Bethune, and G. Picchio Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data AIDS Research and Human Retroviruses 26 2010 621 624
29. A.I. Maiga, D. Descamps, L. Morand-Joubert, I. Malet, A. Derache, M. Cisse, V. Koita, A. Akonde, B. Diarra, and M. Wirden Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes Antimicrobial Agents and Chemotherapy 54 2010 728 733
30. E.L. Asahchop, M. Oliveira, M.A. Wainberg, B.G. Brenner, D. Moisi, T. Toni, and C.L. Tremblay Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes Antimicrobial Agents and Chemotherapy 55 2011 600 607
31. M.T. Lai, M. Lu, P.J. Felock, R.C. Hrin, Y.J. Wang, Y. Yan, S. Munshi, G.B. McGaughey, R.M. Tynebor, and T.J. Tucker Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors Antimicrobial Agents and Chemotherapy 54 2010 4812 4824
32. A.L. McCormick, C.M. Parry, A. Crombe, R.L. Goodall, R.K. Gupta, P. Kaleebu, C. Kityo, M. Chirara, G.J. Towers, and D. Pillay Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1 Antimicrobial Agents and Chemotherapy 55 2011 1806 1809
33. J.H. Brehm, D.L. Koontz, C.L. Wallis, K.A. Shutt, I. Sanne, R. Wood, J.A. McIntyre, W.S. Stevens, N. Sluis-Cremer, and J.W. Mellors Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors Clinical Infectious Diseases 55 2012 737 745
34. C.J. Cohen, J.M. Molina, P. Cahn, B. Clotet, J. Fourie, B. Grinsztejn, H. Wu, M.A. Johnson, M. Saag, and K. Supparatpinyo Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials Journal of Acquired Immune Deficiency Syndromes 60 2012 33 42
35. L. Rimsky, J. Vingerhoets, V. Van Eygen, J. Eron, B. Clotet, A. Hoogstoel, K. Boven, and G. Picchio Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis Journal of Acquired Immune Deficiency Syndromes 59 2012 39 46
36. I. Lisovsky, S.M. Schader, J.L. Martinez-Cajas, M. Oliveira, D. Moisi, and M.A. Wainberg HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes Antimicrobial Agents and Chemotherapy 54 2010 2878 2885
37. J.L. Martinez-Cajas, M.A. Wainberg, M. Oliveira, E.L. Asahchop, F. Doualla-Bell, I. Lisovsky, D. Moisi, E. Mendelson, Z. Grossman, and B.G. Brenner The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors Journal of Antimicrobial Chemotherapy 67 2012 988 994
38. A.F. Santos, D.M. Tebit, M.S. Lalonde, A.B. Abecasis, A. Ratcliff, R.J. Camacho, R.S. Diaz, O. Herchenroder, M.A. Soares, and E.J. Arts Effect of natural polymorphisms in the HIV-1 CRF02-AG protease on protease inhibitor hypersusceptibility Antimicrobial Agents and Chemotherapy 56 2012 2719 2725
39. L. Doyon, G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors Journal of Virology 70 1996 3763 3769
40. C.M. Parry, M. Kolli, R.E. Myers, P.A. Cane, C. Schiffer, and D. Pillay Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity Antimicrobial Agents and Chemotherapy 55 2011 1106 1113
41. J. Ghosn, C. Delaugerre, P. Flandre, J. Galimand, I. Cohen-Codar, F. Raffi, J.F. Delfraissy, C. Rouzioux, and M.L. Chaix Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen PLoS ONE 6 2011 e24798
42. J.A. Bartlett, H.J. Ribaudo, C.L. Wallis, E. Aga, D.A. Katzenstein, W.S. Stevens, M.R. Norton, K.L. Klingman, M.C. Hosseinipour, and J.A. Crump Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings AIDS 26 2012 1345 1354
43. J.K. Rockstroh, H. Teppler, J. Zhao, P. Sklar, M.D. Miller, C.M. Harvey, K.M. Strohmaier, R.Y. Leavitt, and B.Y. Nguyen Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies AIDS 25 2011 1365 1369
44. M.Q. Fish, R. Hewer, C.L. Wallis, W.D. Venter, W.S. Stevens, and M.A. Papathanasopoulos Natural polymorphisms of integrase among HIV type 1-infected South African patients AIDS Research and Human Retroviruses 26 2010 489 493
45. C. Garrido, A.M. Geretti, N. Zahonero, C. Booth, A. Strang, V. Soriano, and C. De Mendoza Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection Journal of Antimicrobial Chemotherapy 65 2010 320 326
46. S. Sierra, N. Lubke, H. Walter, E. Schulter, S. Reuter, G. Fatkenheuer, M. Bickel, H. da Silva, R. Kaiser, and S. Esser The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes Medical Microbiology and Immunology 200 2011 225 232
47. T. Bar-Magen, D.A. Donahue, E.I. McDonough, B.D. Kuhl, V.H. Faltenbacher, H. Xu, V. Michaud, R.D. Sloan, and M.A. Wainberg HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays AIDS 24 2010 2171 2179
48. C. Garrido, V. Soriano, A.M. Geretti, N. Zahonero, S. Garcia, C. Booth, F. Gutierrez, I. Viciana, and C. de Mendoza Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience Antiviral Research 90 2011 164 167
49. P.K. Quashie, T. Mesplede, Y.S. Han, M. Oliveira, D.N. Singhroy, T. Fujiwara, M.R. Underwood, and M.A. Wainberg Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir Journal of Virology 86 2012 2696 2705
50. T. Bar-Magen, R.D. Sloan, D.A. Donahue, B.D. Kuhl, A. Zabeida, H. Xu, M. Oliveira, D.J. Hazuda, and M.A. Wainberg Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor Journal of Virology 84 2010 9210 9216
51. A.M. Geretti, L. Harrison, H. Green, C. Sabin, T. Hill, E. Fearnhill, D. Pillay, and D. Dunn Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy Clinical Infectious Diseases 48 2009 1296 1305
52. A.U. Scherrer, B. Ledergerber, V. von Wyl, J. Boni, S. Yerly, T. Klimkait, P. Burgisser, A. Rauch, B. Hirschel, and M. Cavassini Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B Clinical Infectious Diseases 53 2011 1143 1152
53. I. Dierynck, S. De Meyer, E. Lathouwers, C. Vanden Abeele, T. Van De Casteele, S. Spinosa-Guzman, M.P. de Bethune, and G. Picchio In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients Antiviral Therapy 15 2010 1161 1169
54. D.A. Cooper, J. Heera, J. Goodrich, M. Tawadrous, M. Saag, E. Dejesus, N. Clumeck, S. Walmsley, N. Ting, and E. Coakley Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection Journal of Infectious Diseases 201 2010 803 813